ArticleJournal of cellular and molecular medicine2025
Aspirin Attenuates Liver Fibrosis via Autophagy Induction.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The impact of hypoxia and glycolysis on liver fibrosis.Journal of translational medicine · 2026Article
- Aspirin Attenuates Liver Fibrosis via Autophagy Induction.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The aim of the present study was to explore the effect of the non-steroidal anti-inflammatory drugs (NSAID) aspirin on the progression of liver fibrosis and to elucidate its underlying mechanisms, with a specific focus on autophagy. In vitro, the rat hepatic stellate cell line HSC-T6 was activated using transforming growth factor-β1 (TGF-β1). Western blot and real-time PCR analysis were employed to investigate the effect of aspirin on HSC-T6 activation and its association with autophagy levels, including key autophagic markers. In vivo study, liver fibrosis was induced in mice via long-term thioacetamide (TAA) administration. The impact of aspirin on liver fibrosis and function was evaluated using Masson's Trichrome and Sirius Red staining to assess collagen deposition, complemented by serum biochemistry analysis. TGF-β1 treatment inhibited autophagic flux in activated HSC-T6 cells, as evidenced by increased LC3II/I and p62 expression. Notably, aspirin effectively attenuated fibrogenesis in these cells, with significantly lower expression levels of α-SMA and collagen I compared to the TGF-β1-treated control group. Concurrently, aspirin restored autophagy flux as indicated by decreased LC3-II/I and p62 levels, and the effect can be reversed by the autophagy inhibitor chloroquine (CQ). In vivo, aspirin administration markedly attenuated liver fibrosis. Mechanistically, aspirin treatment enhanced autophagic flux, as demonstrated by the accumulation of autolysosomes observed in liver tissues via transmission electron microscopy (TEM). Our study demonstrates that aspirin inhibits liver fibrosis progression by inducing autophagy, highlighting its potential as a therapeutic strategy for liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.